Department of Pathology, Hacettepe University School of Medicine, Sihhiye, Ankara, Turkey.
Department of Pathology, Mardin State Hospital, Mardin, Turkey.
Virchows Arch. 2018 Jun;472(6):969-974. doi: 10.1007/s00428-018-2302-8. Epub 2018 Jan 24.
Non-invasive low-grade papillary urothelial carcinoma (NILGPUC) of the bladder is regarded as a relatively indolent disease. However, its propensity for frequent recurrences constitutes a major clinical problem. Additionally, there is a progression risk of 10-15% to either a higher grade and/or a higher stage disease in these tumors. The molecular factors that will predict recurrence and progression in low-grade pTa bladder carcinoma have not yet been elucidated. Herein, we investigated the association of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) alterations with recurrence and progression in NILGPUC using immunohistochemistry. Eighty-one cases of bladder cancer initially diagnosed as NILGPUC in a single institution with follow-up were encountered after searching medical records. Tissue microarrays (TMA) that contained both tumor and non-neoplastic mucosa from each case were constructed using paraffin blocks of transurethral resections. Sections from TMA blocks were stained immunohistochemically for PTEN protein and were evaluable in 76 cases. Any absence of staining was recorded and correlated with clinical findings. Ten patients (13.2%) showed progression and 41 (53.9%) showed recurrence. Reduced PTEN expression was observed in 29 cases (38.1%). Cases with reduced PTEN had higher progression rate compared to cases with intact PTEN (p = 0.026). Tumor relapse was more frequent in cases with reduced PTEN (65.5 vs 46.8%), but this difference was not statistically significant (p = 0.112). On the other hand, decreased PTEN expression was associated with higher number of recurrence episodes (p = 0.002). PTEN seems to have a link with the disease course in NILGPUC of the bladder.
膀胱非浸润性低级别乳头状尿路上皮癌(NILGPUC)被认为是一种相对惰性的疾病。然而,其频繁复发的倾向构成了一个主要的临床问题。此外,这些肿瘤有 10-15%的进展风险,可能发展为更高分级和/或更高分期的疾病。预测低级别 pTa 膀胱癌复发和进展的分子因素尚未阐明。在此,我们通过免疫组织化学研究了磷酸酶和张力蛋白同源物缺失的染色体 10(PTEN)改变与 NILGPUC 复发和进展的关系。在单机构搜索病历后,共发现 81 例最初诊断为 NILGPUC 的膀胱癌病例有随访资料。使用经尿道切除术的石蜡块构建包含每个病例的肿瘤和非肿瘤黏膜的组织微阵列(TMA)。从 TMA 块的切片用 PTEN 蛋白进行免疫组织化学染色,并可评估 76 例。记录任何缺失的染色并与临床发现相关联。10 例(13.2%)患者出现进展,41 例(53.9%)患者出现复发。29 例(38.1%)观察到 PTEN 表达减少。与 PTEN 完整的病例相比,PTEN 表达减少的病例进展率更高(p=0.026)。PTEN 表达减少的病例肿瘤复发更频繁(65.5%比 46.8%),但差异无统计学意义(p=0.112)。另一方面,PTEN 表达减少与更高的复发次数相关(p=0.002)。PTEN 似乎与膀胱 NILGPUC 的疾病过程有关。